Business
Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers
Starlight Therapeutics Inc., a Lantern subsidiary, will focus exclusively on the clinical development of therapies for CNS (central nervous system) and brain
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nStarlight Therapeutics Inc., a Lantern subsidiary, will focus exclusively on the clinical development of therapies for CNS (central nervous system) and brain cancers with limited or no effective therapeutic options.\n\n\nLantern's AI platform, RADR®, aided in the identification and accelerated development of Starlight's portfolio of therapeutic indications.\n\n\nThe leading drug candidate, STAR-001, has demonstrated blood-brain barrier permeability, has favorable brain tumor bioavailability, and has shown nanomolar potency across an extensive number of in-vitro and in-vivo CNS and brain cancer models.\n\n\nClinical trials in adult and pediatric CNS cancer indications are anticipated for late 2023 and early 2024.\n\n\nGlobally, STAR-001’s targeted treatment indications represent an anticipated 500,000+ new cases each year and have a combined estimated annual market potential of over $6 billion (USD).\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has formed a wholly-owned subsidiary, Starlight Therapeutics Inc. (“Starlight”), to develop drug candidate LP-184’s central nervous system (CNS) and brain cancer indications – including glioblastoma (GBM), brain metastases (brain mets.), and several rare pediatric CNS cancers. Starlight will refer to the molecule LP-184, as it is developed in CNS indications, as “STAR-001”. Combined, STAR-001’s targeted treatment indications are estimated to represent an annual global market potential of approximately $6.0 billion (USD) and over 500,000 global cases each year.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005304/en/Starlight Therapeutics Pipeline of Adult and Pediatric CNS Cancer Indications (Graphic: Business Wire)\nStarlight plans on establishing a leading CNS oncology franchise to develop the unique drug candidate STAR-001 for some of the most malignant and unaddressed primary and secondary CNS cancers. The programs being developed by Starlight were born from the analysis of billions of oncology-focused data points and by using Lantern’s AI platform,...